In the past decade and a half, the introduction of new therapeutic agents has revolutionized
the management of pulmonary arterial hypertension (PAH). These new treatment options …

Rationale: Limited information is available on racial/ethnic differences in pulmonary arterial
hypertension (PAH). Objectives: Determine effects of race/ethnicity and ancestry on mortality …

Background In recent years, the population of patients with pulmonary arterial hypertension
(PAH) has changed dramatically, including more advanced age at diagnosis. We …

This study explores the racial and ethnic differences in presentation, severity, and treatment
of patients with pulmonary arterial hypertension (PAH) in a large multicenter registry. African …

BACKGROUND Prior research has suggested that the prevalence and outcomes of
pulmonary arterial hypertension (PAH) may vary by race or ethnicity. However, these studies …

(1) Introduction. Although pulmonary arterial hypertension (PAH) usually affects young
people with a low cardiovascular risk profile, progressive epidemiologic changes have been …

The first descriptions of pulmonary arterial hypertension (PAH) have fascinated clinicians
and scientists since these brief initial descriptions. Despite significant advances in the …

But the diverse molecular pathways that lead to the same endresult are lost by WHO
classifications, which are driven by a diagnosis of exclusion, using common tests to prove …

Since 2000 there have been major advances in our understanding of the genetic and
genomics of pulmonary arterial hypertension (PAH), although there remains much to …

Pulmonary arterial hypertension (PAH) is a rare disease that can be caused by (likely)
pathogenic germline genomic variants. In addition to the most prevalent disease gene …